Supernus Pharmaceuticals
SUPN
57 hedge funds and large institutions have $187M invested in Supernus Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
50% more call options, than puts
Call options by funds: $15.1M | Put options by funds: $10M
47% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 17
10% more capital invested
Capital invested by funds: $170M → $187M (+$16.5M)
8% more funds holding
Funds holding: 53 → 57 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MOACM
Mutual of America Capital Management
New York
|
+$1.07M |
| 2 |
RP
Reinhart Partners
Mequon,
Wisconsin
|
+$1M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$963K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$718K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$672K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$12.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.58M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$637K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$502K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$472K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Credit Agricole
Montrouge Cedex,
France
| $49K | +$44.6K | +6,647 | New |
|
52
Citigroup
New York
| $48K | +$39.3K | +5,857 | +933% |
|
53
Bank of America
Charlotte,
North Carolina
| $44K | -$99.6K | -14,833 | -71% |
|
54
Creative Planning
Overland Park,
Kansas
| $22K | +$20.1K | +3,000 | New |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| $20K | -$48.2K | -7,174 | -72% |
|
56
California Public Employees Retirement System
Sacramento,
California
| $1K | – | – | – |
|
57
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $11 | -$1.94K | -289 | -16% |
|
58
Nomura Holdings
Tokyo,
Japan
| – | -$228K | -35,387 | Closed |
|
59
Citadel Advisors
Miami,
Florida
| – | -$56.2K | -8,365 | Closed |
|
|
MCM
60
Mazama Capital Management
Portland,
Oregon
| – | -$40K | -6,250 | Closed |
|
61
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$10.4K | -1,550 | Closed |
|
SUPN Hedge Fund Activity: Q3 2013 in Review
57 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2013, worth a combined $187M — up 9.7% from $170M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SUPN positions and 5 closed out — a net gain of 4 holders — while 25 added to existing stakes and 17 trimmed.
The largest buyer was Mutual of America Capital Management, adding an estimated $1.07M. The largest seller was OrbiMed, cutting an estimated $12.5M.
- 57 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2013, up from 53 in Q2 2013.
- Funds reported $187M of Supernus Pharmaceuticals stock for Q3 2013, up 9.7% quarter-over-quarter.
- 9 funds opened new Supernus Pharmaceuticals positions in Q3 2013 and 5 closed out, a net change of +4 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2013 was Mutual of America Capital Management, an estimated $1.07M added.
- The largest Supernus Pharmaceuticals seller in Q3 2013 was OrbiMed, an estimated $12.5M sold.
Based on aggregated 13F filings for Q3 2013.